Nasdaq
$2.06▼ 2.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $19.9MShares out 9.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 8.24Pre-market26.08.24 13:15filedEFFECTOther#●●●#●●●
Seres Therapeutics, Inc.
The registration statement (File No. 333-298309) filed by Seres Therapeutics was declared effective by the SEC on August 21, 2026. This effectiveness allows the company to officially proceed with the securities offering and capital raising activities outlined in the filing.…more
$2.06-2.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.18After-hours26.08.19 06:334Ownership
Seres Therapeutics, Inc.
Insider Brady Kelly of Seres Therapeutics filed an SEC Form 4 on August 18, 2026, reporting changes in beneficial ownership of company securities as of August 15, 2026. This filing serves as a standard disclosure regarding the insider's equity holdings.…more
$2.06-2.14%vs prev closeView filingShare - 8.18After-hours26.08.19 06:274Ownership
Seres Therapeutics, Inc.
Director Eric D. Shaff of Seres Therapeutics reported a change in his beneficial ownership of company securities as of August 15, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$2.06-2.14%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 20:00#●●●#●●●
Seres Therapeutics to Present Preclinical Data for SER-428 at IDWeek 2026…more
Seres Therapeutics will present preclinical data for SER-428, an oral liquid biotherapeutic designed to reduce bloodstream infection risks in critically ill patients, at IDWeek 2026. Further clinical development of the program remains contingent upon securing additional funding.…more
$2.06-2.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8After-hours26.09.09 07:00
●●●●●●●● ●●●●● ●●●●●●
Seres Therapeutics announced the grant of stock options for 4,200 shares to two new employees as an employment inducement. This is a standard recruitment practice and does not have a material impact on the company's financial outlook.…more
$2.06-2.14%vs prev close - 9.1Pre-market26.09.01 20:00
●●●●●●●● ●●●●● ●●●●●●
Seres Therapeutics announced that its management will present a company overview at the upcoming H.C. Wainwright 28th Annual Global Investment Conference. This event is a standard corporate presentation and does not contain new material financial information.…more
$2.06-2.14%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report